V-HEFT II

V-HEFT II

What is the role of enalapril in male patients with HF and LV dilation or a LV ejection fraction < 45%?

Study design

Population

• 804 male patients
• Inclusion criteria: male patients with HF and LV dilation or an LV ejection fraction < 45%
• Key exclusion criteria: myocardial infarction or cardiac surgery within the previous three months, angina pectoris limiting exercise or requiring long-term medical therapy, serious obstructive valvular disease, or obstructive lung disease

Interventions

• N=403 enalapril (20 mg daily)
• N=401 hydralazine-isosorbide dinitrate arm (300 mg
  hydralazine plus 160 mg isosorbide dinitrate daily)

Primary outcome

Significant decrease in death at 2 years (18% vs. 25%; RR 0.72, 95% CI 0.13 to 1.31)

Secondary outcomes

No significant difference in death in presence of CAD (14.1% vs. 14.3%; RR 0.87, 95% CI 0.64 to 1.19)

Conclusion

In male patients with HF and LV dilation or an LV ejection fraction < 45%, enalapril was superior to hydralazine-isosorbide dinitrate arm with respect to death at 2 years.